Загрузка...
Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies
Large B cell lymphoma (LBCL) is curable with standard chemo-immunotherapy in the majority of cases. However, patients with primary refractory or relapsed disease have historically had limited treatment options. Two gene-modified chimeric antigen receptor (CAR)-T cell therapies have now been approved...
Сохранить в:
| Опубликовано в: : | Mol Ther |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Gene & Cell Therapy
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7854294/ https://ncbi.nlm.nih.gov/pubmed/33130313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2020.10.022 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|